Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with intraperitoneal alpha-2a interferon.

M O Nicoletto1, M V Fiorentino, O Vinante

  • 1Division of Medical Oncology, University Hospital, Padua, Italy.

Oncology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine levels in colostrum and in foals' serum pre- and post-suckling.

Veterinary immunology and immunopathology·2017
Same author

Performance of the Multidimensional Geriatric Assessment and Multidimensional Prognostic Index in predicting negative outcomes in older adults with cancer.

European journal of cancer care·2016
Same author

Hodgkin's Disease in 50 Intravenous Drug Users with HIV-Infection.

Leukemia & lymphoma·2016
Same author

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

West Nile Virus Surveillance in the Lombardy Region, Northern Italy.

Transboundary and emerging diseases·2015
Same author

Treating cancer in older and oldest old patients.

Current pharmaceutical design·2015
Same journal

Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar.

Oncology·2026
Same journal

SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance.

Oncology·2026
Same journal

Letter to the Editor.

Oncology·2026
Same journal

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Oncology·2026
Same journal

Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study.

Oncology·2026
Same journal

Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021.

Oncology·2026
See all related articles

Intraperitoneal alpha 2a-Interferon showed effectiveness in treating epithelial ovarian cancer patients with microscopic disease. This treatment resulted in significant remission rates with manageable toxicity, including fever and mild neurological effects.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Epithelial ovarian cancer is a significant cause of cancer-related mortality.
  • Intraperitoneal chemotherapy is a common treatment modality for ovarian cancer.
  • Alpha 2a-Interferon is a biologic agent with potential anti-cancer properties.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of intraperitoneal alpha 2a-Interferon in patients with epithelial ovarian cancer.
  • To assess the response rates in patients with microscopic peritoneal disease.

Main Methods:

  • Eighteen patients with epithelial ovarian cancer received intraperitoneal alpha 2a-Interferon.
  • The standard dosage was 54 x 10(6) U weekly for four cycles, extended to eight cycles for responders.
  • Patients were assessed for remission and toxicity.

Related Experiment Videos

Main Results:

  • Ten complete remissions and three partial remissions were achieved.
  • The majority of patients experienced fever; some had abdominal discomfort.
  • One patient had a mild, transient neurological complication.

Conclusions:

  • Intraperitoneal alpha 2a-Interferon is effective in treating microscopic peritoneal epithelial ovarian cancer in pretreated patients.
  • The treatment demonstrates a favorable efficacy profile with moderate toxicity.
  • Further investigation into its role in ovarian cancer management is warranted.